These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 33862419)
1. Increased proportion of CD20+ T cells after rituximab treatment in patient with neuromyelitis optica later diagnosed with lung B-cell lymphoma: A case report. Lee JK; Kwon S; Han JH; Yoon SE; Kim BJ; Kang ES J Neuroimmunol; 2021 Jun; 355():577564. PubMed ID: 33862419 [TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical CD20-negative change in B-cell non-Hodgkin lymphomas after rituximab-containing therapy. Maeshima AM; Taniguchi H; Fujino T; Saito Y; Ito Y; Hatta S; Yuda S; Makita S; Fukuhara S; Munakata W; Suzuki T; Maruyama D; Izutsu K Ann Hematol; 2020 Sep; 99(9):2141-2148. PubMed ID: 32451711 [TBL] [Abstract][Full Text] [Related]
3. Changes in B and T-cell subsets and NMO-IgG levels after immunoglobulins and rituximab treatment for an acute attack of neuromyelitis optica. de Andrés C; Teijeiro R; Saiz A; Fernández P; Sánchez-Ramón S Neurologia; 2015 Jun; 30(5):276-82. PubMed ID: 24674779 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis. Wang Y; Chang H; Zhang X; Yin L Mult Scler Relat Disord; 2021 May; 50():102843. PubMed ID: 33609924 [TBL] [Abstract][Full Text] [Related]
5. Individualized B cell-targeting therapy for neuromyelitis optica spectrum disorder. Kim SH; Hyun JW; Kim HJ Neurochem Int; 2019 Nov; 130():104347. PubMed ID: 30513364 [TBL] [Abstract][Full Text] [Related]
6. Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders. Ciron J; Audoin B; Bourre B; Brassat D; Durand-Dubief F; Laplaud D; Maillart E; Papeix C; Vukusic S; Zephir H; Marignier R; Collongues N; Rev Neurol (Paris); 2018 Apr; 174(4):255-264. PubMed ID: 29606320 [TBL] [Abstract][Full Text] [Related]
7. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. Ayzenberg I; Kleiter I; Schröder A; Hellwig K; Chan A; Yamamura T; Gold R JAMA Neurol; 2013 Mar; 70(3):394-7. PubMed ID: 23358868 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and safety of IBI301 versus rituximab in patients with CD20 Jiang B; Ke X; Zhang Q; Xu W; Su H; Huang J; Zhang M; Wang H; Jin C; Zhu J; Liu L; Cai Z; Zhao X; Zhou J; Zhang X; Liu J; Zhou H; Yu J; Sun X; Qi J; Qiu L Sci Rep; 2020 Jul; 10(1):11676. PubMed ID: 32669656 [TBL] [Abstract][Full Text] [Related]
9. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up. Evangelopoulos ME; Andreadou E; Koutsis G; Koutoulidis V; Anagnostouli M; Katsika P; Evangelopoulos DS; Evdokimidis I; Kilidireas C J Neurol Sci; 2017 Jan; 372():92-96. PubMed ID: 28017256 [TBL] [Abstract][Full Text] [Related]
10. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. Kim SH; Huh SY; Lee SJ; Joung A; Kim HJ JAMA Neurol; 2013 Sep; 70(9):1110-7. PubMed ID: 23897062 [TBL] [Abstract][Full Text] [Related]
11. Anti-CD20 monoclonal antibody (Rituximab) for therapy of mediastinal CD20-positive large B-cell non-Hodgkin lymphoma with a local tumor extension into the lung of a 10-year-old girl. Culić S; Culić V; Armanda V; Kuljis D; Pesutić-Pisac V; Janković S Pediatr Hematol Oncol; 2003 Jun; 20(4):339-44. PubMed ID: 12746167 [TBL] [Abstract][Full Text] [Related]
12. Rituximab-induced interstitial lung disease in a patient with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder. Ahn SH; Kim SM; Sung JJ Mult Scler Relat Disord; 2018 Feb; 20():192-193. PubMed ID: 29414297 [TBL] [Abstract][Full Text] [Related]
15. Individualized rituximab treatment for relapsing neuromyelitis optica: a pediatric case report. He D; Yu Y; Yan W; Dai Q; Xu Z; Chu L Pediatr Neurol; 2014 Aug; 51(2):255-8. PubMed ID: 25079575 [TBL] [Abstract][Full Text] [Related]
16. Favorable outcome of granulocyte colony-stimulating factor use in neuromyelitis optica patients presenting with agranulocytosis in the setting of rituximab. Mealy MA; Levy M J Neuroimmunol; 2015 Oct; 287():29-30. PubMed ID: 26439958 [TBL] [Abstract][Full Text] [Related]
17. Effectiveness of rituximab in neuromyelitis optica: a meta-analysis. Gao F; Chai B; Gu C; Wu R; Dong T; Yao Y; Zhang Y BMC Neurol; 2019 Mar; 19(1):36. PubMed ID: 30841862 [TBL] [Abstract][Full Text] [Related]
18. 20 years of rituximab treatment: what have we learnt? Renner C Future Oncol; 2019 Dec; 15(36):4119-4121. PubMed ID: 31718346 [No Abstract] [Full Text] [Related]
19. Nineteen episodes of recurrent myelitis in a woman with neuromyelitis optica and systemic lupus erythematosus. Nasir S; Kerr DA; Birnbaum J Arch Neurol; 2009 Sep; 66(9):1160-3. PubMed ID: 19752308 [TBL] [Abstract][Full Text] [Related]
20. Complement-Dependent Activity of CD20-Specific IgG Correlates With Bivalent Antigen Binding and C1q Binding Strength. Bondza S; Marosan A; Kara S; Lösing J; Peipp M; Nimmerjahn F; Buijs J; Lux A Front Immunol; 2020; 11():609941. PubMed ID: 33505398 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]